LISENSE MEDICAL Co-CEOs Kim Geonho and Choi Uigyeong Buy 30,000 Company Shares

LISENSE MEDICAL, a company specializing in precision-cooling medical devices, has moved to return value to shareholders.

LISENSE MEDICAL disclosed on November 9 that its co-CEOs, Kim Geonho and Choi Uigyeong, had purchased approximately 30,000 of the company's shares on the open market.

The share purchases were made because the co-CEOs believe the current decline in the stock price does not adequately reflect the company's fundamental technological competitiveness and business potential. Based on their firm confidence in the company's underlying fundamentals and future growth prospects, the two co-CEOs decided to make the purchases to demonstrate directly to shareholders their strong commitment to responsible management.

Building on its unrivaled rapid precision-cooling technology, proven by the U.S. FDA's De Novo authorization for a novel medical technology, and its drug-delivery technology using microparticles, LISENSE MEDICAL continues to drive innovation in the medical and aesthetic device sectors. The company is also strengthening its medium- to long-term growth drivers by accelerating the global expansion of its Coolroa 600 product into markets including Japan and Hong Kong.

A company representative said, "The co-CEOs' share purchases reflect their belief that the current stock price is excessively undervalued relative to the company's corporate value, as well as senior management's unwavering confidence in the company's medium- to long-term growth prospects. We will continue to enhance shareholder value through innovative product development and sustained growth, and live up to the market's trust."

This content was produced with the assistance of AI translation services.